PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Penicillamine - Rheumatoid arthritis
PAD Profile : Penicillamine - Rheumatoid arthritis Important
Keywords :
Shared Care
Brand Names Include :
Distamine
Important Information :
Severe disease only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network considers the prescribing of penicillamine in rheumatoid arthritis in NEW patients to be RED – specialist ONLY drugs - treatment initiated and continued by specialist clinicians.
Please note:
- Penicillamine is no longer used routinely (see guidelines from BSR and BHPR below).
- For any new patients initiated on penicillamine, prescribing should be retained by the specialist.
- For the small number of patients currently taking penicillamine in primary care, monitoring requirements should be as described in the current BNF and SPC.
Primary care monitoring requirements for people on penicillamine are available from CKS at: https://cks.nice.org.uk/dmards#!scenario:12
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs